歐康維視生物-B(01477.HK)與綠葉製藥訂立合作及獨家推廣協議
格隆匯 10 月 30日丨歐康維視生物-B(01477.HK)發佈公告,公司間接全資附屬公司歐康維視(浙江)醫藥有限公司已與綠葉製藥(02186.HK)的附屬公司山東博安生物技術有限公司訂立合作及獨家推廣協議,以共同開發正在進行III期臨牀試驗的OT-702(LY09004)(EYLEA® (阿柏西普)的生物類似藥)。此外,浙江歐康維視已獲授獨家權利,以在中國大陸推廣及商業化OT-702。作為代價,浙江歐康維視將在協議簽署後向博安生物支付前期付款,並在達成若干開發及監管里程碑後,支付開發里程碑付款,以及於OT-702獲准於地區內銷售後,支付若干銷售提成及銷售里程碑付款。
根據協議,浙江歐康維視承擔地區內OT-702的III期臨牀試驗相關的所有費用,該等III期臨牀試驗所產生的所有臨牀試驗數據及研發成果將由浙江歐康維視及博安生物共同擁有。協議的期限將至OT-702上市許可批准並完成第一批發貨之日後十年。
公告表示,公司致力於眼科藥物的識別、開發及商業化,在不斷加強其研發能力的同時,公司亦積極開拓與國內外製藥公司就開發多種眼科藥物及產品展開的深入合作。與博安生物共同開發並進行OT-702的III期臨牀試驗的合作乃符合公司將更多中階至商業階段產品引進其產品組合的策略。公司認為,合作將進一步加強其濕性老年黃斑病變領域的產品組合,並加快推動OT-702的臨牀試驗及商業化,以滿足國內患者迫切的臨牀需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.